Debating the Risks of Animal-to-Human Organ Transplants
Executive Summary
Debate continues swirling around the issues of animal-to-human organ transplant, stirring up ethical concerns as well as scientific ones. This much is certain: the companies involved in the area saw potential problems coming a long time ago, but placed bets they hoped would establish them as leaders in a new and lucrative market. Those bets may yet pay off, but the players will now be watched far more closely than they were just a few years ago.
You may also be interested in...
Start-Up Spotlight: Elypta Targets World’s First Metabolism-Based Early Cancer Diagnosis
The Swedish liquid biopsy start-up expects to be the first company to secure US FDA approval for a metabolism-based urine test for the early detection of kidney cancer in post-surgery patients.
Bayer Ponders Road Less Traveled And Trip Savings In Pandemic
Like most CEOs in pharma, Bayer chief Werner Baumann was constantly on the move but "since the middle to the end of the first quarter last year, I haven't traveled at all."
Viatris And Biocon Line Up EU Bevacizumab
Viatris’ Mylan has received a positive opinion from the EMA’s CHMP for its bevacizumab biosimilar rival to Avastin under two different names. Meanwhile, Accord has received an endorsement for a generic version of Zytiga.
Need a specific report? 1000+ reports available
Buy Reports